Skip Navigation LinksNational Health Insurance Fund > News > How do manufacturers share the Lithuanian market of reimbursable medicines
News
How do manufacturers share the Lithuanian market of reimbursable medicines
2018-03-23

​​​Last year, reimbursable medicines were offered by 106 manufacturers of medicinal products in Lithuania For the medicines manufactured, they received more than 217.7 million euros from the Compulsory Health Insurance Fund (CHIF) budget and about 54.2 million euros from the consumers.


According to the data available to the National Health Insurance Fund (NHIF) under the Ministry of Health, last year, the following foreign pharmaceutical companies were the leaders in Lithuania by sales volume of reimbursable medicines (funds from the CHIF budget and the patients): Novartis Europharm (sold reimbursable medicines for the total amount of 20.6 million euros), Les Laboratoires Servier (19.6 million euros), Berlin-Chemie (about 19.1 million euros). For the full list of manufacturers of medicinal products, please click here.


In 2017, Novartis Europharm received the highest amount from the CHIF budget for reimbursable medicines, i.e. a total of 19.7 million euros or about 9 percent of the annual CHIF budget expenditure on medicines. Johnson & Johnson received about 18 million euros or 8.3 percent of the annual CHIF budget expenditure on medicines; Abb Vie – over 14 million euros or 6.5 percent of the annual expenditure.


In the meantime, the following pharmaceutical companies received the highest amount of funds paid for reimbursable medicines directly by consumers: Les Laboratoires Servier – about 10.5 million euros (the portion covered by consumers amounted to 53 percent of the sale price of reimbursable medicines); Berlin-Chemie – 8.7 million euros (the portion covered by consumers amounted to 45 percent of the sale price), KRKA – almost 5 million euros (the portion covered by consumers amounted to 45 percent of the sale price).


According to experts, patients purchasing cardiac medications cover the highest portion of the sale price. For example, in 2017, the portion of the price of cardiac medications of the aforesaid manufacturers covered by consumers was 44–57 percent of the total amount generated from the sale of these medications. Experts note that consumers prefer cardiac medications of well-known manufacturers that are already familiar to them rather than the cheapest ones. But in this case, they have to cover the larger portion of the price.


Statistics show that the largest sale volume of reimbursable medicines and medical aids was achieved by Eurovaistinė UAB (69.3 million euros), Nemuno Vaistinė UAB (about 64 million euros) and Gintarinė Vaistinė UAB (55.1 million euros). For the full list, please click here.


The largest portion of the price of reimbursable medicines and medical aids was covered by consumers purchasing these in Eurovaistinė UAB – a total of 18.9 million euros (the average additional payment per prescription was about 5.4 euros), Nemuno Vaistinė UAB – a total of 15.7 million euros (the average additional payment per prescription was about 5.2 euros), and Gintarinė Vaistinė UAB – a total of 9 million euros (the average additional payment per prescription was about 4.8 euros).


According to the data available to NHIF, last year, reimbursable  medicines and medical aids were consumed by about 1.2 million individuals covered by the compulsory health insurance or about 43 percent of the total population of Lithuania. Half of all the consumers of reimbursable​ medicines and medical aids were individuals older than 60.

 

NHIF information

 

NHIF invites you:

 

 Your questions are welcome by email info@vlk.lt or phone: local  8 700 88888, international   +370 5 236 4114

How do manufacturers share the Lithuanian market of reimbursable medicines